Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.50 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20008975 | 0.91 | ACHE (0.53) | BCHECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL21064727 | 0.88 | BCHE (0.57) | BCHECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23582968 | 0.85 | BCHE (0.61) | BCHECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL23582969 | 0.85 | BCHE (0.61) | BCHECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL29921060 | 0.85 | FUCA1 (0.54) | BCHEMAOBKDM4EACHE | |
| SCHEMBL18081018 | 0.84 | BCHE (0.61) | BCHECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL20012547 | 0.81 | BCHE (0.62) | BCHECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL13411424 | 0.81 | CYP2D6 (0.60) | BCHECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10281961 | 0.81 | CYP2D6 (0.60) | BCHECYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL19844795 | 0.81 | CYP2D6 (0.60) | BCHECYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | BCHE 3469/4885CYP1A2 4326/4885CYP3A4 4379/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | BCHE 3469/4885CYP1A2 4326/4885CYP3A4 4379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.